Prolonged survival after systemic immune reactivation by aglatimagene besadenovec plus valacyclovir in immune checkpoint inhibitor-refractory non-small cell lung cancer.
J Immunother CancerSep 28, 2026 (epub)
Charu Aggarwal, Daniel Sterman, Jessica Dwyer et al.
✦ AI-curated · Sources linked
In 30 seconds
This phase 2a clinical trial evaluated the combination of aglatimagene besadenovec and valacyclovir in 76 patients with immune checkpoint inhibitor-refractory non-small cell lung cancer. The study found a median overall survival of 14.3 months in the safety population and 24.5 months in the evaluable population. The objective response rate was 10.9%.
Key findings
- Median overall survival was 14.3 months in the safety population and 24.5 months in the evaluable population.
- The objective response rate was 10.9% (5/46) in the evaluable population.
- The disease control rate was 71.7% (33/46) in the evaluable population.
- Among 41 evaluable patients, 37% were alive at ≥24 months.
Why it matters
The findings suggest that aglatimagene besadenovec combined with valacyclovir may offer a new therapeutic option for patients with advanced non-small cell lung cancer who have limited treatment choices after immune checkpoint inhibitors.